Investigational drug · Phase 2
FLX475
Also called: tivumecirnon
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "FLX475"
First trial start
2018
Sep 25, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FLX475", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "FLX475" as an intervention, largest first.
- Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompleted
RAPT Therapeutics, Inc., a member of the GSK plc group of companiesIndustry
NCT03674567 · 323 participants · Start Sep 25, 2018 · Primary completion Dec 31, 2024
Drug: FLX475 (tivumecirnon); pembrolizumab (KEYTRUDA®) · For: Advanced Cancer
Sites: Gilbert, Arizona; Duarte, California; Los Angeles, California · 35 sites in all
Hanmi Pharmaceutical Company LimitedIndustry
NCT04768686 · 20 participants · Start May 18, 2021 · Primary completion Aug 12, 2024
Drug: FLX475; Pembrolizumab · For: Gastric Cancer
Sites: Anyang-si, South Korea; Seongnam-si, South Korea; Suwon, South Korea · 10 sites in all
RAPT Therapeutics, Inc., a member of the GSK plc group of companiesIndustry
NCT04894994 · 6 participants · Start Sep 3, 2021 · Primary completion Sep 13, 2022
Drug: FLX475; Ipilimumab · For: Advanced Melanoma
Sites: Los Angeles, California; Tampa, Florida; St Louis, Missouri · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor Immunity.
Robles O, Brockstedt DG, Aponte-Guzman J, et al. · J Med Chem 2026
- Structure basis for C-C chemokine receptor 4 modulation by orthosteric and allosteric antagonists.
Zhou N, Wang R, Chen B, et al. · Proc Natl Acad Sci U S A 2026
- CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2-CCL2, CCR5-CCL5, CCR4-CCL17/22, CCR6-CCL20, CCR7-CCL19/21.
Bahng I · Front Immunol 2026
Also in development for Advanced Cancer
- ObrixtamigBI 764532Phase 36 trials
Boehringer Ingelheim · Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- EzabenlimabBI 754091Phase 32 trials
Boehringer Ingelheim · Advanced Cancer, Neoplasm Metastasis, Advanced Tumors
- ALK201Phase 22 trials
Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors
- CVM-1118TRX-818Phase 22 trials
TaiRx, Inc. · Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors
- KB707Phase 22 trials
Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- Personalized Neoantigen Peptide VaccinePhase 22 trials
Seqker Biosciences, Inc. · Solid Tumors, Advanced Cancer, Recurrent Cancer
- TST001Phase 22 trials
Transcenta Therapeutics (Hangzhou) Co., Ltd. · Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.